Advertisement

Clinical Drug Investigation

, Volume 26, Issue 12, pp 681–690 | Cite as

Functional Half-Life is a Meaningful Descriptor of Steady-State Pharmacokinetics of an Extended-Release Formulation of a Rapidly Cleared Drug

As Shown by Once-Daily Divalproex-ER
  • Sandeep DuttaEmail author
  • Ronald C. Reed
Original Research Article

Abstract

Background: For many drugs, steady-state concentration-time profiles are often not optimally characterised by the intrinsic terminal elimination half-life for various reasons, including multiexponential disposition with minimal contribution of the terminal phase to steady-state exposure or use of controlled-release formulations with extended zero- or mixed zero-/first-order absorption. In such cases, ‘effective’ or ‘functional’ half-life (t1/2F) has often been used to characterise steady-state pharmacokinetics. Valproic acid, commonly used in neuropsychiatry, has an elimination half-life of 4–16 hours in different populations (children vs adults, enzyme-induced vs uninduced). Divalproex-ER, a once-daily extended-release divalproex sodium formulation, is designed to release valproic acid over >18 hours. Hence the steady-state divalproex-ER concentration-time profiles have small peak-trough fluctuations that are not optimally characterised by valproic acid elimination half-life. In this study, the value of t1/2F was calculated to characterise divalproex-ER steady-state concentration-time profiles.

Methods: The value of t1/2F, defined as the time taken for the concentration to drop by one-half during a dosing interval (τ) at steady state, was derived using steady-state maximum (Cmax) and minimum (Cmin) plasma concentration and τ values, and calculated as ln(2)/(ln [Cmax/Cmin]/τ). The t1/2F values of valproic acid in adult hepatic enzyme-uninduced healthy subjects and enzyme-induced epilepsy patients were calculated from five pharmacokinetic studies in which divalproex-ER was administered once daily for 6–14 days.

Results: The estimated geometric mean t1/2F in uninduced adults was 40.0 hours versus the expected elimination half-life of 12–16 hours in this population (including patients on valproic acid monotherapy); for induced patients, t1/2F was 26.9 hours versus the expected elimination half-life of 6–12 hours.

Conclusion: The t1/2F of valproic acid optimally characterises the expected steady-state Cmax to Cmin decrease of 33% in uninduced and 45% in induced adults following once-daily administration of divalproex-ER.

Keywords

Valproic Acid Dose Interval Breakthrough Seizure Valproic Acid Monotherapy Monoexponential Decline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This study was sponsored by Abbott Laboratories, who also employ the authors.

References

  1. 1.
    Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995; 35(8): 763–6PubMedGoogle Scholar
  2. 2.
    Davies RO, Gomez HJ, Irvin JD, et al. An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol 1984; 18Suppl. 2: 215S–29SPubMedCrossRefGoogle Scholar
  3. 3.
    Beermann B, Till AE, Gomez HJ,et al. Pharmacokinetics of lisinopril (IV/PO) in healthy volunteers. Biopharm Drug Dispos 1989; 10(4): 397–409PubMedCrossRefGoogle Scholar
  4. 4.
    Till AE, Gomez HJ, Hichens M, et al. Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 1984; 5(3): 273–80PubMedCrossRefGoogle Scholar
  5. 5.
    Williams PE, Brown AN, Rajaguru S, et al. Pharmacokinetics of cilazapril during repeated oral dosing in healthy young volunteers. Eur J Drug Metab Pharmacokinet 1990; 15(1): 63–7PubMedCrossRefGoogle Scholar
  6. 6.
    Kaiser G, Ackermann R, Brechbuhler S, et al. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril HC1 (CGS 14 824 A) in healthy volunteers after single and repeated administration. Biopharm Drug Dispos 1989; 10(4): 365–76PubMedCrossRefGoogle Scholar
  7. 7.
    King JN, Mauron C, Kaiser G. Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. Am J Vet Res 1995; 56(12): 1620–82PubMedGoogle Scholar
  8. 8.
    Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41(5): 898–905PubMedGoogle Scholar
  9. 9.
    Levy RH, Shen DD, Abbott FS, et al. Chapter 84: Valproic acid — chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al. Anti-epileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 780Google Scholar
  10. 10.
    Gugler R, von Unruh GE. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1980; 5: 67–83PubMedCrossRefGoogle Scholar
  11. 11.
    Zaccara G, Messori A, Moroni F. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 1988; 15: 367–89PubMedCrossRefGoogle Scholar
  12. 12.
    Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 2004; 44(7): 737–42PubMedCrossRefGoogle Scholar
  13. 13.
    Dutta S, Reed RC. Divalproex to divalproex extended release conversion. Clin Drug Invest 2004; 24(9): 495–508CrossRefGoogle Scholar
  14. 14.
    Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982Google Scholar
  15. 15.
    Slavik RS, Jewesson PJ. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet 2003; 42(9): 793–817PubMedCrossRefGoogle Scholar
  16. 16.
    Dutta S, Reed RC. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets. J Clin Pharmacol 2006; 46: 952–7PubMedCrossRefGoogle Scholar
  17. 17.
    Almeida L, Falcao A, Maia J, et al. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005; 45(9): 1062–6PubMedCrossRefGoogle Scholar
  18. 18.
    Domenech J, Lauroba J, Moreno J, et al. A relationship between biological half-life and effective half-life according to pharmacological response in non-steroid antiinflammatory drugs. Arzneimittel Forschung 1981; 31(3): 445–52PubMedGoogle Scholar
  19. 19.
    Keller F, Czock D, Zellner D, et al. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling. Int J Clin Pharmacol Ther 1998; 36(3): 168–75PubMedGoogle Scholar
  20. 20.
    Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991; 74(1): 53–63PubMedCrossRefGoogle Scholar
  21. 21.
    Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76(3): 334–41PubMedCrossRefGoogle Scholar
  22. 22.
    Bailey JM. Technique for quantifying the duration of intravenous anesthetic effect. Anesthesiology 1995; 83(5): 1095–103PubMedCrossRefGoogle Scholar
  23. 23.
    Bailey JM. Context-sensitive half-times and other decrement times of inhaled anesthetics. Anesth Analg 1997; 85(3): 681–6PubMedGoogle Scholar
  24. 24.
    Bailey JM. Context-sensitive half-times: what are they and how valuable are they in anaesthesiology? Clin Pharmacokinet 2002; 41(11): 793–9PubMedCrossRefGoogle Scholar
  25. 5.
    Robbie GJ, Marroum PJ. Dependence of effective half-life on estimation method [abstract no. #1047]. American Association of Pharmaceutical Scientists Annual Meeting 1999, New Orleans (LA)Google Scholar
  26. 26.
    Reed RC, Dutta S, Cavanaugh H, et al. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations. Epilepsy Behav 2006; 8(2): 391–6PubMedCrossRefGoogle Scholar
  27. 27.
    McCabe PH, Michel NC, McNew CD, et al. Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up. Epilepsy Behav 2006; 8(3): 601–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Abbott LaboratoriesAbbott ParkUSA

Personalised recommendations